Built in Johannesburg for South African users
Muscle Guard is made by Brand Expert (Pty) Ltd in Johannesburg. ZAR pricing is the primary display — not a regional after-thought. Compounded semaglutide and tirzepatide are first-class citizens in the medication picker. POPIA compliance is built in, not retrofitted.
What South African GLP-1 users face in 2026
- Cost is the #1 barrier. Branded Ozempic runs R2,700-R3,100/month. Maintenance dose semaglutide or tirzepatide costs R3,000-R6,000/month. Public sector access is essentially non-existent.
- Medical aid coverage is rare. Even on hospital plans, GLP-1 medications for weight management are typically not covered without a chronic-condition motivation. Some Discovery Health benefit categories cover for diabetes but not weight loss.
- Compounded preparations are mainstream. Most South African users on a GLP-1 are on compounded semaglutide or tirzepatide from a registered compounding pharmacy — typically R1,000-R2,500/month.
- Generic semaglutide expected widely available in 2026. Spotlight has reported pricing pressure increasing through the year. The cost barrier should ease meaningfully.
- Mounjaro registered for diabetes only. Tirzepatide is registered with SAHPRA for type 2 diabetes; weight-loss use is off-label.
Frequently asked — South Africa
Is Muscle Guard available on Discovery Vitality?
Not yet. We are in discussion about Vitality Health integration. The app works fully without it.
Can I log compounded semaglutide or tirzepatide?
Yes. Compounded preparations are first-class citizens in Muscle Guard. You can configure custom dose schedules to match your prescriber's regimen.
Does the app work offline?
Yes for basic logging. AI plate scan and Personal Coach require connectivity.
POPIA compliance?
Yes. Muscle Guard is built to POPIA standards. Your data is encrypted, lives in EU-region cloud storage (or on-device), and is deletable in one tap.
Do you have Afrikaans / isiZulu / Sesotho support?
English first. Other South African languages are on the roadmap once user demand justifies the translation cost.